May 12th 2024
Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Phase 1 Study Evaluates Combinations of EPI-7386 for Prostate Cancers
April 24th 2023A phase 1 trial of EPI-7386 will evaluate the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity of the agent in combination with apalutamide or abiraterone acetate plus prednisone.
Read More
Roundtable Discussion: Zakharia Considers Next-Line Therapy Sequencing for mCRPC
April 17th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Yousef Zakharia, MD, discussed next-line therapy for a patient with metastatic castration-resistant prostate cancer who has received docetaxel and an androgen receptor–targeted therapy.
Read More
Higher Dose of Apalutamide for mCRPC and mCSPC Now Available in the United States
April 10th 2023A new apalutamide tablet has become available for oncologists in the United States who treat non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
Read More
ARAMIS Reinforces Findings from ARASENS and Other Studies of Darolutamide in nmCRPC
April 4th 2023In an interview with Targeted Oncology, Neal D. Shore, MD, FACS, gave an overview of previous and updated findings from the ARAMIS trial for patients with nonmetastatic castration-resistant prostate cancer.
Read More
Enzalutamide/Leuprolide Extends MFS in nmHSPC With High-Risk Bochemical Recurrence
March 17th 2023The phase 3 EMBARK trial of enzalutamide plus leuprolide is the first to elicit a statistically significant improvement in metastasis-free survival in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
Read More
Roundtable Discussion: Yu and Participants Assess the Role of PSMA Therapy for mCRPC
March 3rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Evan Y. Yu, MD, discussed with participants role of prostate-specific membrane antigen in metastatic castration-resistant prostate cancer.
Read More
Pembrolizumab Misses Survival End Points in mCRPC/NSCLC
March 1st 2023The phase 3 KEYNOTE-641 of pembrolizumab, enzalutamide, and androgen deprivation therapy has been discontinued, and overall survival rates in the phase KEYNOTE-789 study of pembrolizumab, pemetrexed, platinum-based chemotherapy did not meet statistical significance.
Read More
FDA Receives NDA for Niraparib Plus Abiraterone and Prednisone for BRCA+ mCRPC
March 1st 2023Data from the second interim analysis of the phase 3 MAGNITUDE study showed that the addition of niraparib to abiraterone acetate and prednisone prolonged survival for patients with metastatic castration-resistant prostate cancer with BRCA mutations.
Read More
Discussing the Long-term Impacts of Darolutamide in Nonmetastatic CRPC
February 26th 2023Discussing his presentation from the 2023 ASCO Genitourinary Symposium, Neal Shore, MD, FACS, looks at the long-term results of the phase 3 ARAMIS study for patients with nonmetastatic castration-resistant prostate cancer on darolutamide.
Watch
Emerging Data Behind 2 Antibody Drug Conjugates for Breast and Prostate Cancer
February 24th 2023Experts addressed ARX788 for patients with HER2-positive breast cancer, and a data update from the update for APEX-01 evaluating ARX517 in patients with prostate cancer was provided during a virtual analyst and investor day.
Read More
Role of Piflufolastat F 18 Reinforced in Prostate Cancer With Low PSA Levels
February 20th 2023The secondary analysis of the phase 3 CONDOR study showed that given prior positron emission tomography, piflufolastat F 18 demonstrated changes in intended management, reinforcing the agent's clinical utility.
Read More
Ra-223 Demonstrates Safety, Efficacy in Managing Bone Metastases in Prostate Cancer
February 17th 2023Patients diagnosed with bone metastatic, castration-resistant prostate cancer and treated with radium-223 showed lower incidences of treatment-related adverse events or treatment discontinuation, particularly when used in the front-line setting.
Read More
PROpel Study of Abiraterone/Olaparib Sustains Benefit in mCRPC
February 17th 2023Though not statistically significant, data from the PROpel study of abiraterone acetate and olaparib were noted to be the longest overall survival results seen in a first-line phase 3 trial in metastatic castration-resistant prostate cancer.
Read More
First-line Treatment With Talazoparib and Enzalutamide Improves rPFS in mCRPC
February 16th 2023Patients with first-line metastatic castration-resistant prostate cancer had improvements in radiographic progression-free survival irrespective of homologous recombination repair status when treated with talazoparib and enzalutamide.
Read More